Abstract #2235
Combined Gadoxetic Acid and Gadofosveset Enhanced Liver MRI: A Feasibility and Parameter Optimization Study
Peter Bannas 1,2 , Utaroh Motosugi 1 , Diego Hernando 1 , Mahdi S Rahimi 3 , James H Holmes 4 , and Scott B Reeder 1,5
1
Department of Radiology, University of
Wisconsin, Madison, Madison, WI, United States,
2
Department
of Radiology, University Medical Center Hamburg-Eppendorf,
Hamburg, Hamburg, Germany,
3
Department
of Biomedical Engineering, University of Wisconsin,
Madison, Madison, WI, United States,
4
Global
MR Applications and Workflow, GE Healthcare, Madison,
WI, United States,
5
Department
of Medical Physics, University of Wisconsin, Madison,
Madison, WI, United States
Gadoxetic acid enhanced hepatobiliary phase MRI is
useful for detection of hypointense liver metastases.
However, vessels and benign cavernous hemangiomas also
appear hypointense on gadoxetic acid enhanced MRI and
may be difficult to distinguish from one another. We
hypothesized that use of an intravascular contrast
agent, gadofosveset trisodium, in addition to gadoxetic
acid, may address this issue. The purpose of this work
was to demonstrate the feasibility of combined use of
these two contrast agents and to optimize MR parameters.
We concluded that combination of the two contrast agents
is feasible and worth testing in a clinical setting.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Click here for more information on becoming a member.
